Alzheimer\'s Disease (AD) is a growing global public health challenge.
This is a definitive overview of how the Ecosystem works in transferring an AD Drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing..
With the approval of aducanumab, the function of the Ecosystem has become apparent.
Also discussed is the critical role of advocacy fundraising for Drug development.
Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models.
Masterfully collating information on the Drug Development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly.
The Development of new therapies is urgently needed, and a complex Ecosystem of organizations has grown to facilitate AD Drug discovery and development.
Alzheimer\'s Disease (AD) is a growing global public health challenge
